UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000001081 |
|---|---|
| Receipt number | R000001314 |
| Scientific Title | Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers |
| Date of disclosure of the study information | 2008/03/16 |
| Last modified on | 2018/12/18 09:00:17 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers
Acronym
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Scientific Title
Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers
Scientific Title:Acronym
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Region
| Japan |
Condition
Condition
Esophageal Cancer, Lung Cancer, Stomach Cancer, Breast Cancer, Ovarian Cancer
Classification by specialty
| Gastroenterology | Hepato-biliary-pancreatic medicine | Pneumology |
| Hematology and clinical oncology | Gastrointestinal surgery | Hepato-biliary-pancreatic surgery |
| Chest surgery | Endocrine surgery | Breast surgery |
| Obstetrics and Gynecology | Oto-rhino-laryngology | Urology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
1)To assess safety of CHP-HER2 and CHP-NY-ESO-1 administered subcutaneously in combination with OK-432 to patients with cancers expressing HER2 and/or NY-ESO-1.
2)To measure immunity to HER2 and NY-ESO-1 (antibody, CD4+ and CD8+ T cells) induced by CHP-HER2 and CHP-NY-ESO-1 in combination with OK-432.
Basic objectives2
Others
Basic objectives -Others
To document tumor responses after immunization with CHP-HER2 and CHP-NY-ESO-1 in combination with OK-432.
Trial characteristics_1
Trial characteristics_2
Pragmatic
Developmental phase
Phase I
Assessment
Primary outcomes
1.Safety of CHP-HER2 and CHP-NY-ESO-1 administered subcutaneously in combination with OK-432 to patients with cancers expressing HER2 and/or NY-ESO-1.
2.Immunity to HER2 and NY-ESO-1 (antibody, CD4+ and CD8+ T cells)
Key secondary outcomes
Tumor responses
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
CHP-HER2 vaccine 300micrograms
CHP-NY-ESO-1 vaccine 100micrograms
OK-432 0.02mg
SQ injection, q2wks, 6 cycles
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1.Histological confirmation of cancer.
2.HER2 expression in tumor cells scored as 1+ or more which should be confirmed by IHC using at least two antibodies (archived issue; see Appendix 1 and Reference 1 for methodology). or NY-ESO-1 expression by reverse transcriptase and polymerase chain reaction (RT-PCR) analysis preferably, or immunohistochemistry
3.Patients must
a.are at high risk of recurrence, more than 25% of probability, after complete resection or even after post-operative adjuvant treatment, and effective adjuvant therapy is not available or refused;
or
b.have metastatic disease, and treatment has failed, or in the situation where effective therapy is not available, or has been refused.
3.Complete recovery from surgery (at least 4 weeks).
4.Laboratory values within the following limits:
Hemoglobin 9.0 g/dL or more(10.0 g/dL if <50 kg)
Neutrophil count 1.5x109/L or more
Lymphocyte count 0.5x109/L or more
Platelet count 100x109/L or more
Serum creatinine 1.8 mg/dL or less
Serum bilirubin 2mg/dL or less
5.Performance status > 70 (Karnofsky Scale) and life expectancy >3 months.
6. Age 20 years or more
Key exclusion criteria
1.Clinically significant heart disease (NYHA Class III or IV).
2.Cardiac dysfunction; less than 50% of ejection fraction by echocardiogram.
3.Immunodeficiency disease.
4.Other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders.
5.Previous bone marrow or stem cell transplant.
6.Metastatic disease to the central nervous system, unless treated and stable.
known HIV antibody positivity.
7.Anaphylactic reaction to previous vaccination.
8.Hypersensitivity to penicillin
Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before study entry (6 weeks for nitrosoureas).
9.Concomitant treatment with steroids. Topical or inhalational steroids are permitted.
10.Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
Pregnancy or nursing .
11.Refusal, by women of childbearing potential, to use medically acceptable means of contraception.
12.Mental impairment that may compromise the ability to give informed consent.
13.Lack of availability for immunological and clinical follow-up assessment.
Target sample size
9
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hiroshi Shiku |
Organization
Mie University Graduate School of Medicine
Division name
Department of Cancer Vaccine, Immuno-Gene Therapy
Zip code
Address
2-174, Ebobashi, Tsu, Mie, 514-8507 Japan
TEL
059-231-5187
kageyama@clin.medic.mie-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Shinichi Kageyama |
Organization
Mie University Graduate School of Medicine
Division name
Department of Immuno-Gene Therapy
Zip code
Address
2-174, Ebobashi, Tsu, Mie, 514-8507 Japan
TEL
059-231-5187
Homepage URL
kageyama@clin.medic.mie-u.ac.jp
Sponsor or person
Institute
Mie University Graduate School of Medicine, Kitano Hospital
Institute
Department
Personal name
Funding Source
Organization
Mie University Graduate School of Medicine
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Ludwig Institute for Cancer Research
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
YES
Study ID_1
NCT00291473
Org. issuing International ID_1
ClinicalTrial.gov (NIH, USA)
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2008 | Year | 03 | Month | 16 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2006 | Year | 05 | Month | 11 | Day |
Date of IRB
Anticipated trial start date
| 2006 | Year | 05 | Month | 01 | Day |
Last follow-up date
| 2009 | Year | 03 | Month | 01 | Day |
Date of closure to data entry
| 2009 | Year | 03 | Month | 01 | Day |
Date trial data considered complete
| 2009 | Year | 03 | Month | 01 | Day |
Date analysis concluded
| 2009 | Year | 03 | Month | 01 | Day |
Other
Other related information
Management information
Registered date
| 2008 | Year | 03 | Month | 16 | Day |
Last modified on
| 2018 | Year | 12 | Month | 18 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001314
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
